Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
More research is needed to determine the potential risks and benefits of testosterone treatment in this population.
A review of the major findings presented at the Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco
Researchers compared switching to Symtuza with staying on an effective regimen of a boosted protease inhibitor plus Truvada.
The single-tablet antiretroviral regimen includes Janssen’s darunavir plus Gilead’s cobicistat, emtricitabine and tenofovir alafenamide.
Largest-ever analysis of bone loss in the HIV population found that treating hep C, taking vitamin D and exercising might be preventive.
A new large study compared the single-tablet regimen with an equivalent containing a different version of tenofovir.
Compared with the older tenofovir, called TDF, the new one, TAF, suppressed the virus as well and offered bone, kidney and lipid benefits.
Those who start antiretroviral (ARV) treatment for HIV soon after diagnosis experience a greater decline in bone mineral density.
HIV-positive people 50 and older who switched from Truvada to Descovy in a recent trial reaped health benefits.
Gilead Sciences has released results from three studies examining the effects of switching from the old tenofovir to the new version.
Previous research on bone loss during the first year on PrEP may have failed to consider poor adherence to the regimen.
After losing bone density during a year on PrEP, young men recouped their losses a year later but didn’t catch up with norms.
The FDA has approved Gilead Sciences’ fixed-dose combination tablet Descovy (emtricitabine/tenofovir alafenamide) for HIV treatment.
Those who begin HIV treatment soon after diagnosis experience more bone loss than those who defer taking antiretrovirals until HIV disease has...
Young men taking PrEP in a recent study saw their levels decline, raising concerns that they may experience fragility later in life.
Truvada (tenofovir/emtricitabine) as pre-exposure prophylaxis (PrEP) causes a small decrease in bone mineral density during the first six mont...
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.